Maybe I don't have all of the facts but something sure doesn't look right. On March 13 the Perseus-Soros Biopharmaceutical Fund sold it's entire stake in ARXT. On Friday the stock dropped 9.45 points after the company issued it's outlook for 2007. By getting out of the stock the fund avoided a $16 million dollar hit. http://www.nypost.com/seven/03152007/business/mucinex_is_hit_by_soros_business_zachery_kouwe.htm http://www.marketwatch.com/news/sto...D9-44FB-A751-D4040CB2B420}&dist=TQP_Mod_mktwN What do you think?